Tumor Dna Articles & Analysis
25 news found
The scientists will collect blood from the patients and will measure the number and kind of tumor cells (cellular residual disease) and DNA (molecular residual disease) released from the tumor in the blood. ...
Liquid biopsy testing offers a complementary alternative to solid tumor testing, which is not always feasible due to insufficient tissue, low quality tissue, or the invasiveness of the procedure. The testing works by isolating cell-free DNA (cfDNA) from blood plasma to uncover circulating tumor DNA (ctDNA). Isolating these ...
SOPHiA GENETICS offers a comprehensive suite of liquid biopsy applications that have helped progress oncology research and tumor mutation profiling. Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA ...
Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis. The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect ...
ByTempus
An inhibition of DGKzeta has been demonstrated to enhance T-cell priming against suboptimal tumor antigens and has the potential to overcome multiple immune-suppressive mechanisms in the tumor microenvironment. ...
ByBayer AG
Meanwhile, complex factors and multiple mechanisms are known to induce drug resistance occurrence or reoccurrence, covering tumor heterogeneity, DNA damage repair, apoptosis inhibition, epithelial-mesenchymal transition, increased drug excretion or reduced absorption, decreased drug activity, altered drug metabolism, altered drug target, and ...
BNCT is a targeted radiation cancer therapy in which neutron beams interact with a boron-bearing compound, taken up selectively by tumors, to create DNA-damaging alpha particles within the tumor cells, sparing neighboring, healthy tissue. BNCT has the potential to deliver highly effective, cell-localized radiation therapy to treat ...
SAGA Diagnostics AB is seeking a talented and highly motivated Bioinformatics Scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies that measure circulating tumor DNA (ctDNA) in minimally-invasive “liquid biopsies” such as a simple blood sample. ...
” Rarecells Inc. is a leading company in the development of innovative non-invasive tests for very Early Cancer Diagnosis based on a proprietary hypersensitive AI-based Circulating Tumor Cells (CTCs) and CTC-DNA detection. Founded in 2012, the firm is headquartered in New York and maintains offices and laboratories in New York and Paris. ...
Using our molecular counting technology, the assay provides absolute quantification of methylated circulating tumor DNA (ctDNA) burden. The purpose of the assay, when it becomes clinically available in Q1 2023, will be to enable clinicians to monitor patients’ responses to therapies, including in late-stage cancers for which minimal residual disease (MRD) ...
Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-004 study, which demonstrate that the Cellworks SingulaTM Therapy Response Index (TRI) is highly predictive of Overall Survival (OS), Disease-Free Survival (DFS) and Mandard-tumor regression grade (TRG) for ...
About FoundationOne®CDx FoundationOne CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using ...
The test integrates genomic and epigenomic signatures to detect disease without the need for tumor tissue. (Abstract 168) Additionally, clinical utility data will demonstrate that the Guardant360® liquid biopsy test detects microsatellite instability-high (MSI-H) status in patients with advanced gastrointestinal cancers at a similar frequency to tissue-based testing1,2. ...
This basket trial will include detection of circulating tumor DNA (ctDNA) across various solid tumors, including lung cancer, breast cancer, sarcoma and gastrointestinal (GI) cancers. ...
The test looks for hundreds of biomarkers in a small amount of tumor tissue, including complex genomic signatures like tumor mutational burden (TMB), homologous recombination deficiency (HRD) and microsatellite instability (MSI) that can determine whether immunotherapy or PARP inhibitors would work for a patient. ...
About FoundationOne CDx FoundationOne CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using ...
THE TWO BELGIAN COMPANIES WILL WORK TOWARDS A BETTER UNDERSTANDING OF NON-SMALL CELL LUNG CANCER BIOLOGY AND CHARACTERIZATION OF THE TUMORS USING AI TECHNOLOGY Radiomics and OncoDNA are pleased to announce that they have entered into a strategic agreement, combining Radiomics’ next-generation AI-based technology to extract quantitative information embedded in medical ...
Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and genomic alteration status confirmed using an FDA-approved tumor tissue test, if feasible. ...
InterX, Inc., a privately-owned company, Philochem, a wholly owned subsidiary of Philogen S.p.A., a publicly-listed company, and Scripps Research, a non-profit American medical research facility, today announced the signature of a research collaboration to discover new small molecule therapeutics using InterX’s proprietary computational chemical biology software platform and ...
ByInterX
RNA sequencing was performed on tumor samples obtained from these patients at initial diagnosis, prior to any systemic treatment. 30 patients (0.9% of all patients and 1.1% of all patients with ER-positive tumors) were found to have an ESR1 mutation already present in their tumor. ...